Investigational drugs for treating agitation in persons with dementia.
作者： Ricardo P. Garay , Leslie Citrome , George T. Grossberg , Icilio Cavero , Pierre-Michel Llorca
DOI: 10.1080/13543784.2016.1193155
关键词:
摘要: ABSTRACTIntroduction: Agitation is common and distressing in persons with dementia, but safe, effective treatments remain elusive. In this review, the authors describe investigational compounds ongoing or recently completed clinical trials for indication provide an opinion on how they may meet current therapeutic needs.Areas covered: Phase II phase III agitation dementia were searched US EU trial registries medical literature period January 2013-February 2016Expert opinion: The searches identified 24 recent investigating new dementia. Candidate drugs development included antipsychotic brexpiprazole, antidepressant citalopram, novel compound AVP-786 (deuterated-dextromethorphan/quinidine combination) cannabinoid nabilone. Of trials, ELND005 (scyllo-inositol) intended to progress into pha...
sci-hub.se 参考文章(81)
Siegfried Tuinier, Wim Verhoeven, Serenics: Anti-aggression drugs throughout history Clinical Neuropsychiatry: journal of treatments evaluation. pp. 135- 143 ,(2007)
Geke A.H. van den Elsen, Amir I.A. Ahmed, Robbert-Jan Verkes, Ton Feuth, Marjolein A. van der Marck, Marcel G.M. Olde Rikkert, Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial The American Journal of Geriatric Psychiatry. ,vol. 23, pp. 1214- 1224 ,(2015) , 10.1016/J.JAGP.2015.07.011
Hui Ma, Yinglin Huang, Zhengtu Cong, Yuan Wang, Wenhai Jiang, Shuhe Gao, Gang Zhu, The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. Journal of Alzheimer's Disease. ,vol. 42, pp. 915- 937 ,(2014) , 10.3233/JAD-140579
Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P Imbimbo, Andrea Santamato, Madia Lozupone, Camilla Prete, Antonio Greco, Alberto Pilotto, Giancarlo Logroscino, Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease Expert Opinion on Pharmacotherapy. ,vol. 16, pp. 2581- 2588 ,(2015) , 10.1517/14656566.2015.1092520
Inga M Antonsdottir, Jessica Smith, Melanie Keltz, Anton P Porsteinsson, Advancements in the treatment of agitation in Alzheimer's disease. Expert Opinion on Pharmacotherapy. ,vol. 16, pp. 1649- 1656 ,(2015) , 10.1517/14656566.2015.1059422
Marco Mula, Investigational new drugs for focal epilepsy Expert Opinion on Investigational Drugs. ,vol. 25, pp. 1- 5 ,(2016) , 10.1517/13543784.2016.1110144
Leslie Citrome, Tine Bryan Stensbøl, Kenji Maeda, The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Review of Neurotherapeutics. ,vol. 15, pp. 1219- 1229 ,(2015) , 10.1586/14737175.2015.1086269
Dallas P Seitz, Nikesh Adunuri, Sudeep S. Gill, Andrea Gruneir, Nathan Herrmann, Paula Rochon, Antidepressants for agitation and psychosis in dementia Cochrane Database of Systematic Reviews. ,(2011) , 10.1002/14651858.CD008191.PUB2
Clive G Ballard, Jonathan Waite, Jacqueline Birks, The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD003476.PUB2
Leslie Citrome, Iftekhar Kalsekar, Ross A. Baker, Tony Hebden, A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults Current Medical Research and Opinion. ,vol. 30, pp. 1629- 1641 ,(2014) , 10.1185/03007995.2014.908280